Browsing Tag
GPCR
2 posts
Structure Therapeutics (Nasdaq: GPCR) posts 16% weight loss with oral GLP-1 drug aleniglipron, setting up Phase 3 push
Structure Therapeutics' aleniglipron hits 16% weight loss at 44 weeks in Phase 2, matching injectables. Read the full analysis before Phase 3 begins.
Deep Apple Therapeutics signs $812m global deal with Novo Nordisk for oral cardiometabolic drugs
Deep Apple inks up to $812M deal with Novo Nordisk to advance oral GPCR drugs for obesity and metabolic diseases. Explore the science behind the strategy.